Sichuan-based pharmaceutical manufacturer selling drugs in China.
Sichuan-based pharmaceutical manufacturer selling drugs in China.
Moat: none
Headquarters: Sichuan, China · Employees: 1,366
Size Sichuan Huiyu Pharmaceutical (688553.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $904M, the 2353rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥9.78 on 18 Nov 2026.
Performance Over six months the shares fell 27.9%, against -16.9% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 20 in its peer set.
Growth Revenue grew 14.0% over the last twelve months (peer median +2.1%); the operating margin is 7.1% (peer median 6.7%).
Valuation It trades at 3.5× enterprise value to sales against a peer median of 3.9× (9th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is -6%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.3 points below its cost of capital (9.1% WACC).
Next results Next results expected around 26 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.12B | CN¥996M | CN¥1.09B | CN¥924M | CN¥1.49B |
| Revenue growth | — | -9% | +18% | -38% | — |
| Gross profit | CN¥888M | CN¥737M | CN¥849M | CN¥759M | CN¥1.28B |
| EBITDA | n/a | CN¥110M | CN¥143M | CN¥69.9M | CN¥185M |
| Net income | CN¥129M | -CN¥25.0M | CN¥325M | CN¥140M | CN¥249M |
| Free cash flow | CN¥101M | CN¥26.4M | CN¥135M | -CN¥194M | -CN¥220M |
| Capital expenditure | CN¥62.8M | CN¥105M | CN¥128M | CN¥297M | CN¥462M |
| Total debt | CN¥725M | CN¥648M | CN¥594M | CN¥436M | CN¥55.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688553.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -10.4% | -9.1% | 9th lowest of 21 |
| 6-month return | -27.9% | -16.9% | 7th lowest of 20 |
| Distance from 52-week high | -43.6% | -44.2% | 10th highest of 21 |
| Revenue growth (TTM) | +14.0% | +2.1% | 8th highest of 19 |
| Operating margin | 7.1% | 6.7% | 10th highest of 19 |
| EV / Sales | 3.5× | 3.9× | 9th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 19.4% | 8.4% | 2nd most demanding of 13 |
| Growth delivered (Del g) | -6.0% | +6.3% | 3rd lowest of 13 |
| Hurdle (Req g minus delivered) | +25.4 pp | -0.8 pp | 2nd most demanding of 13 |
| ROIC minus cost of capital | -2.3 pp | -0.2 pp | 6th lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | 3.5× | 19.4% | -6.0% |
| Genfleet Therapeutics (Shanghai) 2595.HK | Hong Kong | $912M | -42% | -55% | -457% | 55.9× | n/a | n/a |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | 33.4× | n/a | n/a |
| Immatics IMTX | United States | $913M | -46% | -44% | -589% | 8.5× | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | 0.9× | -7.6% | -0.7% |
| MoonLake Immunotherapeutics MLTX | United States | $918M | -37% | n/a | n/a | n/a | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $921M | -37% | +67% | 21% | 2.6× | -3.7% | +13.8% |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $922M | -14% | +2% | 24% | 5.2× | 9.1% | +13.4% |
| Oscotec 039200.KS | South Korea | $923M | -32% | +510% | 59% | 7.5× | -10.2% | +18.1% |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| Bio-Thera Solutions 688177.SS | China | $929M | -23% | +24% | -44% | 6.5× | n/a | n/a |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $936M | -10% | -43% | -42% | 4.5× | 10.3% | -13.7% |
| KPC Pharmaceuticals 600422.SS | China | $940M | -6% | -41% | -10% | 1.8× | n/a | n/a |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $941M | -9% | -16% | 13% | 2.8× | 7.7% | -6.9% |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $869M | -26% | +23% | 36% | 8.3× | 17.7% | +22.7% |
| Pharming PHARM.AS | Netherlands | $867M | -6% | +2% | 9% | 2.2× | 2.4% | +12.4% |
| SK Discovery 006120.KS | South Korea | $866M | +25% | +24% | 3% | 0.8× | n/a | n/a |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $866M | -26% | -6% | 5% | 4.1× | 31.7% | +4.2% |
| Ningbo Menovo Pharmaceutical 603538.SS | China | $945M | -48% | +19% | 9% | 3.8× | 11.6% | +4.9% |
| Strides Pharma Science STAR.NS | India | $946M | -17% | +11% | 14% | 2.0× | 17.6% | +7.8% |
| SSY 2005.HK | Hong Kong | $948M | +8% | -4% | 12% | 2.2× | 2.3% | -0.5% |